Enzymology of bioreductive drug activation

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Ross, D ^a   Beall, H D ^a   Siegel, D ^a   Traver, R D ^a   Gustafson, D L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; CARBONYL REDUCTASE; CYTOCHROME P450 REDUCTASE; MITOMYCIN C; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RUFOCROMOMYCIN; SEMIQUINONE; TIRAPAZAMINE; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; AZIRIDINE DERIVATIVE; INDOLE DERIVATIVE; MITOMYCIN;

CANCER CELL CULTURE; CONFERENCE PAPER; CYTOTOXICITY; DNA CROSS LINKING; DNA POLYMORPHISM; DNA STRAND BREAKAGE; DRUG ACTIVATION; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYMOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PH; PRIORITY JOURNAL; REDUCTION; SOLID TUMOR; ANIMAL; BIOTRANSFORMATION; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; INDOLEQUINONES; INDOLES; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION;

EID: 0029997868     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (89)

1. ALLEY SC, BRAMELD KA AND HOPKINS PB. (1994). DNA interstrand cross-linking by 2,5-bis(1-aziridinyl)-1,4-benzoquinone: nucleotide sequence preferences and covalent structure of the dG-to-dG cross-links at 5′-d(GNnC) in synthetic oligonucleotide duplexes. J. Am. Chem. Soc., 116, 2734-2741.
2. BACHUR NR, GORDON SL, GEE MV AND KON H. (1979). NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl Acad. Sci. USA, 76, 954-957.
3. BEALL HD, MULCAHY RT, SIEGEL D, TRAVER RD, GIBSON NW AND ROSS D. (1994). Metabolism of bioreductive antitumor quinones by purified rat and human DT-diaphorases. Cancer Res., 54, 3196-3201.
4. BEALL HD, MURPHY AM, SIEGEL D, HARGREAVES RHJ, BUTLER J AND ROSS D. (1995). NAD(P)H:quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones. Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol. Pharmacol., in press.
5. BEGLEITER A, LEITH M, MCCLARTY G, BENNKEN S, GOLDENBERG GJ AND WRIGHT JA. (1988). Cancer Res., 48, 1727-1735.
6. BEGLEITER A, ROBOTHAM E, LACEY G AND LEITH MK. (1989). Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett., 45, 173-176.
7. BELCOURT MF, HODNICK WF, KEMPLE B, ROCKWELL S AND SARTORELLI AC. (1995). Induction of differential toxicity to mitomycin antibiotics by overexpression of NADPH:cytochrome c (P-450) reductase in Chinese hamster ovary (CHO) cells. Proc. Am. Assoc. Cancer Res., 36, 602.
8. BERGER MS, TALCOTT RE, ROSENBLUM ML, SILVA M, ALIOSMAN F AND SMITH MT. (1985). The use of quinones in brain tumor chemotherapy. Preliminary results from preclinical investigations. J. Toxicol. Environ. Health, 16, 713-719.
9. BLIGH HFJ, BARTOSZEK A, ROBSON CN, HICKSON ID, KASPER CB, BEGGS JD AND WOLF CR. (1990). Activation of mitomycin C by NADPH:cytochrome P-450 reductase. Cancer Res., 50, 7789-7792.
10. BOLAND MP, KNOX RJ AND ROBERTS JJ. (1991). The differences in kinetics of rat and human DT-diaphorase result in differential sensitivity of derived cell lines to CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol., 41, 867-875.
11. BUFFINGTON GD, OLLINGER K, BRUNMARK A AND CADENAS E. (1989). DT-diaphorase-catalysed reduction of 1,4- naphthoquinone derivatives and glutathionyl-quinone conjugates. Biochem. J., 257, 561-571.
12. BUTLER J AND HOEY BM. (1993). The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase. Biochim. Biophys. Acta, 1161, 73-78.
13. CADENAS E. (1995). Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol., 49, 127-140.
14. CLARKE ED, GOULDING KH AND WARDMAN P. (1982). Nitroimidazoles as anaerobic electron acceptors for xanthine oxidase. Biochem. Pharmacol., 31, 3237-3242.
15. CLARKE ED, WARDMAN P AND GOULDING KH. (1980). Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase. Biochem. Pharmacol., 29, 2684-2687.
16. CONE R, HASAN SK, LOWN JW AND MORGAN AR. (1976). The mechanism of the degradation of DNA by streptonigrin. Can. J. Biochem., 54, 219-223.
17. CORRAN HS, GREEN DE AND STRAUB FB. (1939). On the catalytic function of heart flavoprotein. Biochem. J., 33, 793-801.
18. CRESTEIL T AND JAISWAL AK. (1991). High levels of expression of the NAD(P)H:quinone oxidoreductase (NQOI) gene in tumor cells compared to normal cells of the same origin. Biochem. Pharmacol., 42, 1021-1027.
19. CROOKE ST AND BRADNER WT. (1976). Mitomycin C: a review. Cancer Treat. Rev., 3, 121-139.
20. DEWAN JG AND GREEN DE. (1938). Coenzyme factor - a new oxidation catalyst. Biochem. J., 32, 626-639.
21. DULHANTY AM AND WHITMORE GF. (1991). Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res., 51, 1860-1865.
22. EDWARDS YH, POTTER J AND HOPKINSON DA. (1980). Human FAD-dependent NAD(P)H diaphorase. Biochem. J., 187, 429-436.
23. EICKELMANN P, EBERT T, WARSKULAT U, SCHULZ WA AND SIES H. (1994). Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases α and π in human renal cell carcinoma and in kidney cancer-derived cell lines. Carcinogenesis, 15, 219-225.
24. ERNSTER L. (1967). DT-diaphorase. Methods Enzymol., 10, 309-317.
25. FITZSIMMONS SA, WORKMAN P, GREVER M, PAULL K, CAMALIER R AND LEWIS AD. (1996). The differential expression of reductase enzymes in the NCI human tumor cell line panel: correlation with sensitivity to mitomycin C and the investigational indoloquinone EO9. J. Natl Cancer Inst., in press.
26. FORREST GL, AKMAN S, DOROSHOW J, RIVERA H AND KAPLAN WD. (1991). Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol. Pharmacol., 40, 502-507.
27. GIBSON NW, HARTLEY JA, BUTLER J, SIEGEL D AND ROSS D. (1992a). Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol. Pharmacol., 42, 531-536.
28. GIBSON NW, SIEGEL D AND ROSS D. (1992b). Mitomycin C. In Cancer Chemotherapy and Biological Response Modifiers Annual 13. Pinedo HM, Longo DL and Chabner BA. (eds) Chapter 5. Elsevier: Amsterdam.
29. GUSTAFSON DL AND PRITSOS CA. (1992a). Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. J. Natl Cancer Inst., 84, 1180-1185.
30. GUSTAFSON DL AND PRITSOS CA. (1992b). Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol. Cancer Res., 52, 6936-6939.
31. HOBAN PR, WALTON MI, ROBSON CN, GODDEN J, STRATFORD IJ, WORKMAN P, HARRIS AL AND HICKSON ID. (1990). Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res., 50, 4692-4697.
32. HODNICK WF, BELCOURT MF, KEMPLE B, ROCKWELL S AND SARTORELLI AC. (1995). Potentiation of mitomycin C and porfiromycin toxicity to Chinese hamster ovary (CHO) cells by overexpression of DT-diaphorase (DTD) cDNA. Proc. Am. Assoc. Cancer Res., 36, 602.
33. 5 reductase. Cancer Res., 53, 4907-4912.
34. HUANG MT, MIWA GT, CRONHEIM N AND LU AYH. (1979). Rat liver cytosolic azoreductase. J. Biol. Chem., 254, 11223-11227.
35. IYANAGI T AND YAMAZAKI I. (1970). Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim. Biophys. Acta, 216, 282-294.
36. IYER VN AND SZYBALSKI W. (1964). Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science, 145, 55-58.
37. JAISWAL AK. (1994). Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J. Biol. Chem., 269, 14502-14508.
38. JAISWAL AK, MCBRIDE OW, ADESNIK M AND NEBERT DW. (1988). Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. J. Biol. Chem., 263, 13572-13578.
39. 2 gene locus on chromosome 6. Biochemistry, 29, 1899-1906.
40. KENNEDY KA, MCGURL JD, LEONDARIDIS L AND ALABASTER O. (1985). pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res., 45, 3541-3547.
41. KEYES SR, FRACASSO PM, HEIMBROOK DC, ROCKWELL S, SLIGAR SG AND SARTORELLI AC. (1984). Role of NADPH:cytochrome c reductase and DT-diaphorase in the bioatransformation of mitomycin C. Cancer Res., 44, 5638-5643.
42. KEYES SR, ROCKWELL S AND SARTORELLI AC. (1985). Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res., 45, 213-216.
43. KEYES SR, ROCKWELL S AND SARTORELLI AC. (1989). Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. Cancer Res., 49, 3310-3313.
44. KNOX RJ, BOLAND MP, FRIEDLOS F, COLES B, SOUTHAN C AND ROBERTS JJ. (1988). The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol., 37, 4671-4677.
45. KNOX RJ, FRIEDLOS F, MARCHBANK T AND ROBERTS JJ (1991). Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol., 42, 1691-1697.
46. KOMIYAMA T, KIKUCHI T AND SUGIURA Y. (1982). Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, in the presence of NADPH-cytochrome P-450 reductase. Biochem. Pharmacol., 31, 3651-3656.
47. LADEROUTE K, WARDMAN P AND RAUTH AM. (1988). Molecular mechanism for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide. Biochem. Pharmacol., 37, 1487-1495.
48. LANGDON SP, HENDRIKS HR, BRAAKHUIS BJM, PRATESI G, BERGER DP, FODSTAD O, FIEBIG HH AND BOVEN E. (1994). Ann. Oncol., 5, 415-422.
49. LEE CS, HARTLEY JA, BERARDINI MD, BUTLER J, SIEGEL D, ROSS D AND GIBSON NW. (1992). Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT- diaphorase. Biochemistry, 31, 3019-3025.
50. LI R, BIANCHET M, TALALAY P AND AMZEL LM. (1995). The three dimensional structure of NAD(P)H:(quinone acceptor) oxidoreductase, a chemoprotective flavoprotein, determined to 2.1 Å resolution. FASEB J., 9, A1338.
51. LIN AJ, COSBY LA, SHANSKY CW AND SARTORELLI AC. (1972). Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J. Med. Chem., 15, 1247-1252.
52. LIND C, CADENAS E, HOCHSTEIN P AND ERNSTER L. (1990). DT-diaphorase: purification, properties and function. Methods Enzymol., 186, 287-301.
53. MALIEPAARD M, WOLFS A, GROOT SE, DE MOL NJ AND JANSSEN LHM. (1995). Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br. J. Cancer, 71, 836-839.
54. MALKINSON AM, SIEGEL D, FORREST GL, GAZDAR AF, OIE HK, CHAN DC, BUNN PA, MABRY M, DYKES DJ, HARRISON JR SD AND ROSS D. (1992). Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res., 52, 4752-4757.
55. MARSHALL RS, PATERSON MC AND RAUTH AM (1989). Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br. J. Cancer, 59, 341-346.
56. MARSHALL RS, PATERSON MC AND RAUTH AM (1991a). Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. Biochem. Pharmacol., 41, 1351-1360.
57. MARSHALL RS, PATERSON MC AND RAUTH AM. (1991b). DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis, 12, 1175-1180.
58. O'DWYER PJ, YAO KS, FORD P, GODWIN AK AND CLAYTON M. (1994). Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon carcinoma cells. Cancer Res., 54, 3082-3087.
59. PAN SS, ANDREWS PA, GLOVER CJ AND BACHUR NR. (1984). Reductive activation of mitomycin C and mitomycin C metabolites catalysed by NADPH:cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem., 259, 959-966.
60. PAN SS, YU F AND HIPSHER C. (1993). Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells. Mol. Pharmacol., 43, 870-877.
61. PATTERSON AV, ROBERTSON N, HOULBROOK S, STEPHENS MA, ADAMS GE, HARRIS AL, STRATFORD IJ AND CARMICHAEL J. (1994). The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int. J. Radiat. Oncol. Biol. Phys., 29, 369-372.
62. PAULL K, CAMALIER R, FITZSIMMONS SA, LEWIS AD, WORKMAN P AND GREVER M. (1994). Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel. Proc. Am. Assoc. Cancer Res., 35, 369.
63. PHILLIPS RM, DE LA CRUZ A, TRAVER RD AND GIBSON NW. (1994). Increased activity and expression of NAD(P)H:quinone acceptor oxidoreductase in confluent cell cultures and within multicellular spheroids. Cancer Res., 54, 3766-3771.
64. PLUMB JA AND WORKMAN P. (1994). Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int. J. Cancer, 56, 134-139.
65. PLUMB JA, GERRITSEN M AND WORKMAN P. (1994). DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br. J. Cancer, 70, 1136-1143.
66. POWIS G AND APPEL PL. (1980). Relationship of the single-electron reduction potential of quinones with their reduction by flavoproteins. Biochem. Pharmacol., 29, 2567-2572.
67. PROCHASKA HJ AND TALALAY P. (1988). Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res., 48, 4776-4782.
68. PROCHASKA HJ, DE LONG MJ AND TALALAY P. (1985). On the mechanisms of induction of cancer-protective enzymes: a unifying proposal. Proc. Natl Acad. Sci. USA, 82, 8232-8236.
69. ROBERTSON N, STRATFORD IJ, HOULBROOK S, CARMICHAEL J AND ADAMS GE. (1992). The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem. Pharmacol., 44, 409-412.
70. ROBERTSON N, HAIGH A, ADAMS GE AND STRATFORD IJ. (1994). Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer, 30A, 1013-1019.
71. ROSS D, SIEGEL D, BEALL H, PRAKASH AS, MULCAHY RT AND GIBSON NW. (1993). DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev., 12, 83-101.
72. ROSS D, BEALL H, TRAVER RD, SIEGEL D, PHILLIPS RM AND GIBSON NW. (1994). Bioactivation of quinones by DT-diaphorase. Molecular, biochemical and chemical studies. Oncol. Res., 6, 493-500.
73. ROSVOLD EA, MCGLYNN KA, LUSTBADER ED AND BUETOW KH. (1993). Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer. Proc. Am. Assoc. Cancer Res., 34, 144.
74. SARTORELLI AC, HODNICK WF, BELCOURT MF, TOMASZ M, HAFFTY B, FISCHER JJ AND ROCKWELL S. (1994). Mitomycin C: a prototype bioreductive agent. Oncol. Res., 6, 501-508.
75. SCHLAGER JJ AND POWIS G. (1990). Cytosolic NAD(P)H:quinone acceptor oxidoreductase in human normal and tumor tissue. Effects of cigarette smoking and alcohol. Int. J. Cancer, 45, 403-409.
76. SHIBATA K, KASAHARA K, BANDO T, NAKATSUMI Y, FUJIMURA M, TSURUO T AND MATSUDA T. (1995). Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions. Jpn. J. Cancer Res., 86, 460-469.
77. SIEGEL D, GIBSON NW, PREUSCH PC AND ROSS D. (1990). Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res., 50, 7483-7489.
78. SIEGEL D, BEALL H, SENEKOWITSCH C, KASAI M, ARAI H, GIBSON NW AND ROSS D. (1992). Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry, 31, 7879-7885.
79. SIEGEE D, BEALL H, KASAI M, ARAI H, GIBSON NW AND ROSS D. (1993). pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol. Pharmacol., 44, 1128-1134.
80. SIEGEE D, TRAVER RD, BEALL HD AND ROSS D. (1995). Cloning and purification of a mutant DT-diaphorase protein from human colon and lung cancer cell lines. Proc. Am. Assoc. Cancer Res., 36, 291.
81. SMITSKAMP-WILMS E, PETERS GJ, PINEDO HM, VAN ARK-OTTE J AND GIACCONE G. (1994). Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem. Pharmacol., 47, 1325-1332.
82. SPAIN RC. (1993). The case for mitomycin in non-small cell lung cancer. Oncology, 50(suppl. 1), 35-52.
83. TRAVER RD, HORIKOSHI T, DANENBERG KD, STADLBAUER THW, DANENBERG PV, ROSS D AND GIBSON NW. (1992). NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res., 52, 797-802.
84. TRAVER RD, PHILLIPS RM, GIBSON NW AND ROSS D. (1995). A point mutation in both human lung and colon carcinoma cell lines leading to a loss of DT-diaphorase activity. Proc. Am. Assoc. Cancer Res., 36, 525.
85. WALTON MI AND WORKMAN P. (1993). Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J. Pharmacol. Exp. Ther., 265, 938-947.
86. WALTON MI, SMITH PJ AND WORKMAN P. (1991). The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun., 3, 199-206.
87. WORKMAN P. (1994). Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol. Res., 6, 461-475.
88. WORKMAN P AND WALTON MI. (1990). Enzyme-directed bioreductive drug development. In Selective Activation of Drugs by Redox Processes, Adams GE, Breccia A, Fielden EM and Wardman P. (eds) pp. 173-191. Plenum: New York.
89. WORKMAN P, WALTON MI, BAILEY SM AND SUGGETT NR. (1991). Enzyme-directed bioreductive drug development: molecular features which favour activation of quinone bioreductives by DT-diaphorase. Br. J. Cancer, 64(suppl. 15), 4.